These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 35995141)

  • 1. Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential.
    Wen Y; Tang F; Tu C; Hornicek F; Duan Z; Min L
    Cancer Lett; 2022 Oct; 547():215887. PubMed ID: 35995141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions.
    Zhang C; Zhang C; Wang H
    Cancer Lett; 2023 May; 562():216182. PubMed ID: 37076040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
    Anderson R; Theron AJ; Rapoport BL
    Front Immunol; 2019; 10():2254. PubMed ID: 31616428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gold digging: Searching for gut microbiota that enhances antitumor immunity.
    Hou F; Pan Z; Yang R; Zhi F; Bi Y
    J Cell Physiol; 2021 Aug; 236(8):5495-5511. PubMed ID: 33452716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treg-mediated acquired resistance to immune checkpoint inhibitors.
    Saleh R; Elkord E
    Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
    Park JA; Cheung NV
    J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Not Available].
    Mignard X; Chaabane N; Fallet V; Wislez M
    Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint inhibitor immunotherapy in kidney cancer.
    Xu W; Atkins MB; McDermott DF
    Nat Rev Urol; 2020 Mar; 17(3):137-150. PubMed ID: 32020040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer combination therapies by silencing of CTLA-4, PD-L1, and TIM3 in osteosarcoma.
    Sorkhabi AD; Sarkesh A; Fotouhi A; Saeedi H; Aghebati-Maleki L
    IUBMB Life; 2022 Sep; 74(9):908-917. PubMed ID: 35638098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
    Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
    Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
    Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
    Yao L; Jia G; Lu L; Bao Y; Ma W
    Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
    Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
    Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
    Zheng B; Ren T; Huang Y; Guo W
    Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse.
    Zheng B; Ren T; Huang Y; Sun K; Wang S; Bao X; Liu K; Guo W
    J Hematol Oncol; 2018 Feb; 11(1):16. PubMed ID: 29409495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology.
    Lee HT; Lee SH; Heo YS
    Molecules; 2019 Mar; 24(6):. PubMed ID: 30917623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translational Biomarkers and Rationale Strategies to Overcome Resistance to Immune Checkpoint Inhibitors in Solid Tumors.
    Chen JA; Ma W; Yuan J; Li T
    Cancer Treat Res; 2020; 180():251-279. PubMed ID: 32215873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.